What is Mendor?
Mendor is a Finnish health technology firm dedicated to the design, development, and marketing of advanced diabetes management products. The company distinguishes itself through a user-centric approach, having developed a revolutionary, portable 3G blood glucose meter paired with a sophisticated web-based software application. By collaborating closely with diabetes experts and patients, Mendor addresses the daily challenges of glucose monitoring, providing a seamless digital ecosystem that empowers users to manage their condition with greater precision and ease. Its market position is defined by the intersection of high-accuracy hardware and data-driven software, positioning it as a key player in the evolving digital health market.
How much funding has Mendor raised?
Mendor has raised a total of $145.6M across 4 funding rounds:
Series B
$11.6M
Private Equity
$6.4M
Debt
$8.8M
Private Equity
$118.8M
Series B (2011): $11.6M with participation from Finnvera Venture Capital, Life Sciences Partners, and Finnish Industry Investment
Private Equity (2014): $6.4M led by Finnvera Venture Capital, Life Sciences Partners, and Finnish Industry Investment
Debt (2014): $8.8M supported by IPF Partners
Private Equity (2016): $118.8M featuring i-SENS Inc and IPF Partners
Key Investors in Mendor
Finnvera Venture Capital
Finnvera is a specialized financing company owned by the State of Finland, acting as the official Export Credit Agency to strengthen the competitiveness of Finnish enterprises.
Life Sciences Partners
A prominent investment firm focused on the life sciences sector, facilitating mergers and asset acquisitions to drive innovation in healthcare and biotechnology.
IPF Partners
IPF Partners is a leading alternative financing provider dedicated exclusively to the healthcare sector, offering tailored debt and equity solutions for medtech and digital health companies.
What's next for Mendor?
With the infusion of $118.8M, Mendor is well-positioned to scale its operations and expand its international footprint. The strategic focus will likely center on enhancing its existing product suite, potentially integrating next-generation sensor technology and expanding its software capabilities to offer more comprehensive health insights. As the company moves into its next phase of growth, it will leverage its established partnerships with industry leaders to penetrate new markets and further optimize its manufacturing and distribution channels. The ongoing support from specialized healthcare investors suggests a long-term commitment to maintaining Mendor's competitive edge in the global diabetes management market.
See full Mendor company page
